Skip to main content

Table 3 Tumour response (n = 31)

From: Evaluation of safety and efficacy of gefitinib ('iressa', zd1839) as monotherapy in a series of Chinese patients with advanced non-small-cell lung cancer: experience from a compassionate-use programme

 

Patients

Complete response, n (%)

1 (3.2)

Partial response, n (%)

10 (32.3)

Stable disease, n (%)

7 (22.6)

Progressive disease, n (%)

11 (35.5)

Early death, n (%)

2 (6.5)

Response rate, % (95% CI)

35.5 (18.6–52.3)

Disease control rate, % (95% CI)

58.1 (49.2–67.0)

  1. CI, confidence interval
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us